Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02667327
Other study ID # 2015-DFU-301
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date November 21, 2018
Est. completion date May 27, 2020

Study information

Verified date May 2020
Source FirstString Research, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.


Description:

DFU patients will undergo a one week screening period and those with changes in ulcer size of less than 30% will be eligible for randomization providing all other criteria are met. Participants enrolled in the study will receive treatment based on randomization into 1 of 3 treatment arms for up to 12 weeks. The participants will have an additional 12 week follow-up period beyond the treatment period to assess durability of wound closure.


Other known NCT identifiers
  • NCT02666131

Recruitment information / eligibility

Status Terminated
Enrollment 124
Est. completion date May 27, 2020
Est. primary completion date May 27, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Both male and female participants may participate in the study.

To be eligible for entry into this study, a patient must meet all of the following Inclusion criteria:

1. Age 18 years or older

2. Established diagnosis of diabetes mellitus (type I or II)

3. Glycosylated hemoglobin (HbA1c) value < 12.0% at the screening visit

4. Diagnosis of neuropathic foot ulcer by 10g monofilament test, tuning fork (128 Hz), or cotton wisp

5. Designated foot ulcer meets the following criteria at both the screening and baseline visits:

1. Present for at least 4 weeks

2. Full-thickness cutaneous ulcer below the ankle surface

3. University of Texas grade A1

4. Wound area (after debridement) 1 to 40.0 cm2

5. Viable, granulating wound (investigator discretion)

6. Ankle brachial index = 0.7 at both the screening and baseline visits. If the ABI is >1.30, one of the following confirmatory tests must be performed for the patient to be considered eligible:

1. Does Not have a monophonic or biphasic flow (with the loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries, as determined by standard practices of the investigator and the site.

2. Transcutaneous oxygen pressure (TcPO2) at the foot >40 mmHg

Additionally, patients must meet all other protocol-defined eligibility criteria.

7. Signed informed consent

8. Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of investigational product. Male patients must also agree to use contraception such as a condom.

Exclusion Criteria:

Patients will not be eligible for enrollment in the study if they meet any of the exclusion criterial listed below:

1. Change (decrease or increase) in size of the designated target ulcer by = 30% during the 7-day screening period

2. Cannot tolerate the off-loading methods or cannot comply with study related procedures

3. Has an ulcer that meets any of the following criteria:

1. Shows signs of severe clinical infection, defined as pus oozing from the ulcer site

2. Requires surgical debridement

3. Is positive for ß-hemolytic streptococci upon culture performed prior to screening debridement procedure

4. Has > 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure

5. Is highly exuding (i.e., requires daily change of dressing)

4. Requires total contact cast

5. Ankle brachial pressure index < 0.7

6. Has a local or systemic infection or local lymphangitis = 0.5 cm

7. Has any 1 of the following (only 1 of the 2 tests is required):

1. A monophasic or biphasic flow (with loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries

2. Transcutaneous oxygen pressure (TcPO2) at the foot <40 mgHg

8. Presence of active malignant or benign tumor of any kind, (with the exception to nonmelanoma skin cancer as per investigator's discretion)

9. Congestive heart failure (New York Heart Association class II-IV)

10. Coronary heart disease with ST segment elevation myocardial infarction or coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the last 6 months

11. Active osteomyelitis of the foot with the target ulcer detected by x-ray, CT scan, or MRI

12. Active connective tissue disease

13. Acute or chronic Charcot's neuro-arthropathy as determined by clinical and/or radiographic examination

14. Active treatment with systemic corticosteroids or topical corticosteroids (for treatment of the target ulcer or any area of the foot). This does not include inhaled corticosteroids used for conditions other than treating the target ulcer or any area of the foot. Wash out period for systemic corticosteroids is 14 days for inclusion in this study. Wash out period for topical corticosteroids (for treatment of the target ulcer or any area of the foot) is 14 days for inclusion in the study)

15. Active treatment with systemic antibiotics (wash out period for systemic antibiotics is 7 days for the inclusion in the study)

16. Previous or current radiation therapy to the distal lower extremity or likelihood to receive this therapy during study participation

17. Pregnant or nursing mothers

18. Uncontrolled anemia (hemoglobin < 10 g/dL in females and < 12 g/dL in males)

19. Estimated glomerular filtration rate < 25 mL/min

20. Poor nutritional status, defined as an albumin < 25 g/L (< 2,500 mg/dl)

21. Significant peripheral edema as per investigator's discretion

22. Known inability or unavailability of a patient to complete required study visits during study participation

23. A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the patient's medical history, which, in the opinion of the investigator, may pose a threat to patient compliance

24. Use of a platelet-derived growth factor within 28 days before screening

25. Use of any investigational drug or therapy within 28 days before screening

26. Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Granexin gel
Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
Other:
Vehicle gel
The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.

Locations

Country Name City State
Canada Centre podiatrique et soins des plaies Boucherville Quebec
Hungary Clinexpert Kft. - Kaszasdulo utca 5. Budapest
Hungary Strazsahegy Medicina Bt., Zrinyi utca 226 Budapest
India Parul Sevashram Hospitals Ahmedabad Gujarat
India Shrey Hospital Pvt Ltd Ahmedabad Gujarat
India KLEs Dr. Prabakar Kore Hospital and Medical Research Center Belgaum
India Peoples College of Medical Science and Research Centre Bhopal
India Marwari Hospital and Research Centre Guwahati
India Surakshaka MultiSpecialty and Diabetes Hospital Hyderabad
India Convenient Hospitals Ltd., CHL - Hospitals Indore Madhya Pradesh
India KRM Hospital and Research Center Lucknow
India Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow
India Fortis Hospital Mohali
India K R Hospital and Research Institute Mysore
India Supe Heart and Diabetes Hospital and Research Centre Nashik
India Batra Hospital and Medical Research Center New Delhi
India Aman Hospital and Research Centre Vadodara
India Anand Multispecialty Hospital Vadodara Gujarat
India Anu Hospitals, Kovelamudivara Street Vijayawada
Poland Lubuskie Centrum Diabetologii UI. Budziszynek Zielon
Poland MIKOMED Sp. z o.o. ul. Lódz . Lódz .Plugowa
Poland Instytut Medycyny Wsi - oddz diabetologii ul. Jaczewskiego 2, 20-090 Lublin, Poland Lublin Jaczewskiego
Poland NZOZ MED ART. Poradnie Specjalistyczne Ks. Wladyslawa 27, 44-240 Zory, Poland Zory Wladyslawa 27
United States Integral - Clinical Trials Solutions Doral Florida
United States Acclaim Bone & Joint Fort Worth Texas
United States Direct Helpers Research Center Hialeah Florida
United States New Hope Podiatry Group, Inc. Los Angeles California
United States Futuro Clinical Trials, LLC McAllen Texas
United States Nirvana Research Center Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
FirstString Research, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Hungary,  India,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of complete wound closure at Week 12 based on investigator assessment Week 12
Secondary Time in days to first complete wound closure of the target ulcer based on investigator assessment over the 12 week treatment period Week 12
See also
  Status Clinical Trial Phase
Completed NCT02652754 - Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers Phase 1
Completed NCT01070433 - A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers Phase 2
Completed NCT00971048 - Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds N/A
Terminated NCT00762138 - The AutoloGel™ Post-Market Surveillance (TAPS) Program N/A
Completed NCT00578604 - Non-Invasive Assessment of Wound Healing With Optical Methods N/A
Completed NCT05417425 - Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers Phase 1
Completed NCT02631512 - Evaluation of Woulgan in Diabetic Foot Ulcer Phase 4
Completed NCT02222376 - Effect of Topic Pirfenidone in Diabetic Ulcers Phase 3
Terminated NCT01816633 - Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers N/A
Completed NCT01221207 - Instant Total Contact Cast to Heal Diabetic Foot Ulcers N/A
Completed NCT01454401 - LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers N/A
Withdrawn NCT01105884 - Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers N/A
Completed NCT01291160 - Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers Phase 2/Phase 3
Completed NCT00536744 - Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers Phase 3
Terminated NCT00316537 - Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers Phase 1/Phase 2
Completed NCT00013299 - Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3 Phase 2
Completed NCT00013286 - A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk Phase 2
Not yet recruiting NCT00916292 - Safety Study of Topical Human FGF-1 for Wound Healing Phase 1
Completed NCT01154374 - A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot) Phase 2
Not yet recruiting NCT02672280 - Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects Phase 1/Phase 2